NEWS & VIEWS
Macrogenics' Koenig talks DART deals, growing pipeline
Friday, July 25, 2014
In the past four years, Macrogenics Inc. has inked five lucrative big pharma partnerships for its bispecific and multispecific antibody platform, most recently a potential $469 million deal with Takeda Pharmaceutical Co. Ltd.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.